Balonová T, Ujházy E, Nosál R, Durisová M, Jakubovský J, Líska J
Ustav experimentálnej farmakológie SAV, Bratislave.
Bratisl Lek Listy. 1991 Dec;92(12):603-8.
The cardioprotective drug stobadine in the form of dipalmitate salt DP 1031 was evaluated for its effects on perinatal and postnatal development in the rat. Doses of 5, 15 and 50 mg/kg/day representing approximately 1, 3, and 10 times the anticipated maximum daily human therapeutic dose were administered to rats orally in aqueous suspension. Treatment of pregnant rats with stobadine continuously from day 15 of gestation through parturition and lactation had no adverse effects on reproductive parameters of dams or on survival and development of F1 offspring at any dose used. There were only signs of slight maternal toxicity at 50 mg/kg/day, which consisted of sedated behaviour, reduced liver weight and reversible histopathological changes in kidney tissue. (Tab. 3, Fig. 4, Ref. 24).
以二棕榈酸盐形式（DP 1031）存在的心脏保护药物司托巴定，其对大鼠围产期和产后发育的影响得到了评估。分别以相当于预期人类最大日治疗剂量约1、3和10倍的5、15和50毫克/千克/天的剂量，将司托巴定以水悬浮液的形式经口给予大鼠。从妊娠第15天开始直至分娩和哺乳期连续用司托巴定处理怀孕大鼠，在所使用的任何剂量下，对母鼠的生殖参数或F1代仔鼠的存活和发育均无不良影响。仅在50毫克/千克/天剂量时有轻微母体毒性迹象，表现为行为镇静、肝脏重量减轻以及肾组织中可逆的组织病理学变化。（表3、图4、参考文献24）
